Home - Australian Pharmacist

Calculating the risk of glaucoma

David Barbeler - December 21, 2018

Clinical

More than 1000 people have completed an online assessment in Australian pharmacies to determine their potential risk of developing glaucoma, and there's a call...

What we know about giving Aussie kids a healthy head start

Abbott - October 26, 2019

Advertorial

Unpredictable eating habits in kids is a problem facing many Australian parents, every day.

Antioxidants and mineral supplements for slowing age-related macular degeneration

Dr Hanan Khalil - September 8, 2017

Clinical

Age-related macular degeneration (AMD) is the most common cause of blindness in developed countries. The prevalence of AMD is 1.4% at 70 years of...

Reducing stroke risk in dementia patients

Thea Cowie - April 30, 2018

Clinical

A commonly-used treatment for Alzheimer's disease could reduce the risk of stroke among people with dementia. The Australian-Swedish study, co-authored by Monash University researchers, focussed...

The new normal

Graem Sims - September 18, 2019

Industry

A new PSA report describes the digital future of Australian health care, a ‘new normal’ with pharmacists front and centre, equipped with more information...

Indirect impacts of COVID-19

Chloe Hava - April 7, 2021

Industry

Australia has had relative success in suppressing the COVID-19 virus, but there continues to be myriad ongoing and wide ranging indirect impacts.

1...278279280...318 Page 279 of 318

ACT³	No comparable criteria
NSW⁴	· pharmacist gives the person an opportunity to seek advice as to the use of the substance · quantity, or for a purpose must accord with the recognised therapeutic standard of what is appropriate in the circumstances
NT⁵	· pharmacist must not intentionally supply to a person in a manner reckless to their circumstance
QLD⁶	· pharmacist reasonably believes the patient has a therapeutic need
SA	No comparable criteria
TAS⁷	· pharmacist forms the opinion use in the treatment of the patient is justified on consideration of the condition, disease or symptoms of the person
VIC⁸	· for treatment of a patient under pharmacist’s care · pharmacist has taken all reasonable steps to ensure a therapeutic need exists
WA⁹	No comparable criteria

ACT³	No comparable criteria
NSW⁴	· pharmacist gives the person an opportunity to seek advice as to the use of the substance · quantity, or for a purpose must accord with the recognised therapeutic standard of what is appropriate in the circumstances
NT⁵	· pharmacist must not intentionally supply to a person in a manner reckless to their circumstance
QLD⁶	· pharmacist reasonably believes the patient has a therapeutic need
SA	No comparable criteria
TAS⁷	· pharmacist forms the opinion use in the treatment of the patient is justified on consideration of the condition, disease or symptoms of the person
VIC⁸	· for treatment of a patient under pharmacist’s care · pharmacist has taken all reasonable steps to ensure a therapeutic need exists
WA⁹	No comparable criteria

ACT³	No comparable criteria
NSW⁴	· pharmacist gives the person an opportunity to seek advice as to the use of the substance · quantity, or for a purpose must accord with the recognised therapeutic standard of what is appropriate in the circumstances
NT⁵	· pharmacist must not intentionally supply to a person in a manner reckless to their circumstance
QLD⁶	· pharmacist reasonably believes the patient has a therapeutic need
SA	No comparable criteria
TAS⁷	· pharmacist forms the opinion use in the treatment of the patient is justified on consideration of the condition, disease or symptoms of the person
VIC⁸	· for treatment of a patient under pharmacist’s care · pharmacist has taken all reasonable steps to ensure a therapeutic need exists
WA⁹	No comparable criteria

ACT³	No comparable criteria
NSW⁴	· pharmacist gives the person an opportunity to seek advice as to the use of the substance · quantity, or for a purpose must accord with the recognised therapeutic standard of what is appropriate in the circumstances
NT⁵	· pharmacist must not intentionally supply to a person in a manner reckless to their circumstance
QLD⁶	· pharmacist reasonably believes the patient has a therapeutic need
SA	No comparable criteria
TAS⁷	· pharmacist forms the opinion use in the treatment of the patient is justified on consideration of the condition, disease or symptoms of the person
VIC⁸	· for treatment of a patient under pharmacist’s care · pharmacist has taken all reasonable steps to ensure a therapeutic need exists
WA⁹	No comparable criteria

Case scenario

Learning objectives

Introduction

Epidemiology

Aetiology and pathophysiology

Risk factors

Clinical features

Management

Knowledge to practice

Case scenario continued

Key points

References

Our author

Our reviewer

1. Therapeutic Guidelines overhaul UTI treatment

2. Is Rikodeine still being rescheduled?

What else was popular?

1. PBS co‑payment will drop

2. Transition to the new MMR credential must be completed

3. Continued freeze on PBS concessional co‑payment

4. Optional allowable discount phase out continues

5. New PSA standards for CPD accreditation launch

Is advance provision of S3s legal?

But don’t we need to assess a patient’s therapeutic need?

So when is advanced supply of S3 OK?

What other things do I need to consider?

So what about the Rikodeine?

Table 1 – Legal requirements for pharmacists when prescribing Schedule 3 medicines

References

Case scenario

Learning objectives

Introduction

Epidemiology

Aetiology and pathophysiology

Risk factors

Clinical features

Management

Knowledge to practice

Case scenario continued

Key points

References

Our author

Our reviewer

1. Therapeutic Guidelines overhaul UTI treatment

2. Is Rikodeine still being rescheduled?

What else was popular?

1. PBS co‑payment will drop

2. Transition to the new MMR credential must be completed

3. Continued freeze on PBS concessional co‑payment

4. Optional allowable discount phase out continues

5. New PSA standards for CPD accreditation launch

Is advance provision of S3s legal?

But don’t we need to assess a patient’s therapeutic need?

So when is advanced supply of S3 OK?

What other things do I need to consider?

So what about the Rikodeine?

Table 1 – Legal requirements for pharmacists when prescribing Schedule 3 medicines

References

Case scenario

Learning objectives

Introduction

Epidemiology

Aetiology and pathophysiology

Risk factors

Clinical features

Management

Knowledge to practice

Case scenario continued

Key points

References

Our author

Our reviewer

1. Therapeutic Guidelines overhaul UTI treatment

2. Is Rikodeine still being rescheduled?

What else was popular?

1. PBS co‑payment will drop

2. Transition to the new MMR credential must be completed

3. Continued freeze on PBS concessional co‑payment

4. Optional allowable discount phase out continues

5. New PSA standards for CPD accreditation launch